The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1)
Abstract
BACKGROUND To investigate the safety and activity of preoperative pembrolizumab combined with chemoradiotherapy for resectable oesophageal squamous cell carcinoma (ESCC) (ClinicalTrials.gov number, NCT03792347). METHODS Twenty resectable ESCC patients, regardless of programmed death ligand-1 status, received preoperative pembrolizumab with concurrent chemoradiotherapy (PPCT). Preoperative therapy includes carboplatin (area under the curve of 2 mg per milliliter per minute, once a week for 5 weeks), paclitaxel (50 mg/m2, once a week for 5 weeks), radiotherapy (23 fractions of 1.8 Gy, 5 fraction a week) and pembrolizumab (2 mg/kg) on days 1 and 22. Within 4-6 weeks after preoperative therapy, patients underwent surgery. The primary end-point was safety and secondary outcome measures were feasibility, pathologic complete response (pCR) rate and radiographic response. Immune signature of CD8+ T cells was evaluated in surgical specimens using immunohistochemistry and immunofluorescence. RESULTS All patients have received PPCT successfully, except one patient who missed the last dose of chemotherapy due to leukopenia. Grade III and higher adverse events (AEs) were observed in 13 patients (13/20, 65%), and one patient had a grade V AE. The most frequent grade III AE was lymphopenia (12/13, 92%). Eighteen patients underwent surgery within 4-9 weeks after PPCT and the pCR rate was 55.6% (10/18). The percentage of transcription factor 1 positive cells was significantly higher in specimens of pCR group than those of non-pCR group (p value = 0.010). CONCLUSIONS PPCT was safe, did not delay surgery, and induced a pCR in 55.6% of resected tumours. A phase II multicentre study is undergoing for further confirmation of efficacy (NCT04435197).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
van Hagen, P., Hulshof, M. C. C. M., van Lanschot, J. J. B., Steyerberg, E. W., Henegouwen, M. I. V. B., Wijnhoven, B. P. L., Richel, D. J., Nieuwenhuijzen, G. A. P., Hospers, G. A. P., Bonenkamp, J. J., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112088 · Cited by 5,521
Shapiro, J., van Lanschot, J. J. B., Hulshof, M. C. C. M., van Hagen, P., van Berge Henegouwen, M. I., Wijnhoven, B. P. L., van Laarhoven, H. W. M., Nieuwenhuijzen, G. A. P., Hospers, G. A. P., Bonenkamp, J. J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00040-6 · Cited by 2,565
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
Sade-Feldman, M., Yizhak, K., Bjorgaard, S. L., Ray, J. P., de Boer, C. G., Jenkins, R. W., Lieb, D. J., Chen, J. H., Frederick, D. T., Barzily-Rokni, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.038 · Cited by 2,053
CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer
McLane, L. M., Abdel-Hakeem, M. S., & Wherry, E. J. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-041015-055318 · Cited by 1,975
Integrated genomic characterization of oesophageal carcinoma
The Cancer Genome Atlas Research Network (2017) · Nature · doi:10.1038/nature20805 · Cited by 1,821
Epidemiology of Esophageal Squamous Cell Carcinoma
Abnet, C. C., Arnold, M., & Wei, W.-Q. (2018) · Gastroenterology · doi:10.1053/j.gastro.2017.08.023 · Cited by 1,672
Blank, C. U., Haining, W. N., Held, W., Hogan, P. G., Kallies, A., Lugli, E., Lynn, R. C., Philip, M., Rao, A., Restifo, N. P., et al. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0221-9 · Cited by 1,603
Kato, K., Cho, B. C., Takahashi, M., Okada, M., Lin, C.-Y., Chin, K., Kadowaki, S., Ahn, M.-J., Hamamoto, Y., Doki, Y., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30626-6 · Cited by 1,213
Identification of genomic alterations in oesophageal squamous cell cancer
Song, Y., Li, L., Ou, Y., Gao, Z., Li, E., Li, X., Zhang, W., Wang, J., Xu, L., Zhou, Y., et al. (2014) · Nature · doi:10.1038/nature13176 · Cited by 1,083
Ajani, J. A., D’Amico, T. A., Bentrem, D. J., Chao, J., Corvera, C., Das, P., Denlinger, C. S., Enzinger, P. C., Fanta, P., Farjah, F., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0033 · Cited by 1,059
Targeting neoantigens to augment antitumour immunity
Yarchoan, M., Johnson, B. A., Lutz, E. R., Laheru, D. A., & Jaffee, E. M. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.154 · Cited by 997
Yang, H., Liu, H., Chen, Y., Zhu, C., Fang, W., Yu, Z., Mao, W., Xiang, J., Han, Y., Chen, Z., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.1483 · Cited by 995
Self-citationSharabi, A. B., Lim, M., DeWeese, T. L., & Drake, C. G. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00007-8 · Cited by 899
An intra-tumoral niche maintains and differentiates stem-like CD8 T cells
Jansen, C. S., Prokhnevska, N., Master, V. A., Sanda, M. G., Carlisle, J. W., Bilen, M. A., Cardenas, M., Wilkinson, S., Lake, R., Sowalsky, A. G., et al. (2019) · Nature · doi:10.1038/s41586-019-1836-5 · Cited by 817
Ohigashi, Y., Sho, M., Yamada, Y., Tsurui, Y., Hamada, K., Ikeda, N., Mizuno, T., Yoriki, R., Kashizuka, H., Yane, K., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1469 · Cited by 796
Genetic landscape of esophageal squamous cell carcinoma
Gao, Y.-B., Chen, Z.-L., Li, J.-G., Hu, X.-D., Shi, X.-J., Sun, Z.-M., Zhang, F., Zhao, Z.-R., Li, Z.-T., Liu, Z.-Y., et al. (2014) · Nature Genetics · doi:10.1038/ng.3076 · Cited by 694
Self-citationGenomic and molecular characterization of esophageal squamous cell carcinoma
Lin, D.-C., Hao, J.-J., Nagata, Y., Xu, L., Shang, L., Meng, X., Sato, Y., Okuno, Y., Varela, A. M., Ding, L.-W., et al. (2014) · Nature Genetics · doi:10.1038/ng.2935 · Cited by 626
Berger, A. C., Farma, J., Scott, W. J., Freedman, G., Weiner, L., Cheng, J. D., Wang, H., & Goldberg, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.017 · Cited by 505
Shah, M. A., Kojima, T., Hochhauser, D., Enzinger, P., Raimbourg, J., Hollebecque, A., Lordick, F., Kim, S.-B., Tajika, M., Kim, H. T., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5441 · Cited by 496
Genomic Landscape of Esophageal Squamous Cell Carcinoma in a Japanese Population
Sawada, G., Niida, A., Uchi, R., Hirata, H., Shimamura, T., Suzuki, Y., Shiraishi, Y., Chiba, K., Imoto, S., Takahashi, Y., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.035 · Cited by 332
Zhang, L., Zhou, Y., Cheng, C., Cui, H., Cheng, L., Kong, P., Wang, J., Li, Y., Chen, W., Song, B., et al. (2015) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2015.02.017 · Cited by 329
Self-citationDoi, T., Piha-Paul, S. A., Jalal, S. I., Saraf, S., Lunceford, J., Koshiji, M., & Bennouna, J. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.9846 · Cited by 318
Kojima, T., Muro, K., Francois, E., Hsu, C.-H., Moriwaki, T., Kim, S.-B., Lee, S.-H., Bennouna, J., Kato, K., Lin, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.4_suppl.2 · Cited by 202
Gong, J., Le, T. Q., Massarelli, E., Hendifar, A. E., & Tuli, R. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0361-7 · Cited by 191
Yagi, T., Baba, Y., Ishimoto, T., Iwatsuki, M., Miyamoto, Y., Yoshida, N., Watanabe, M., & Baba, H. (2019) · Annals of Surgery · doi:10.1097/sla.0000000000002616 · Cited by 182
Kato, K., Shah, M. A., Enzinger, P., Bennouna, J., Shen, L., Adenis, A., Sun, J.-M., Cho, B. C., Özgüroğlu, M., Kojima, T., et al. (2019) · Future Oncology · doi:10.2217/fon-2018-0609 · Cited by 171
Leng, X., He, W., Yang, H., Chen, Y., Zhu, C., Fang, W., Yu, Z., Mao, W., Xiang, J., Chen, Z., et al. (2019) · Annals of Surgery · doi:10.1097/sla.0000000000003727 · Cited by 100
Self-citationWan, T., Zhang, X.-F., Liang, C., Liao, C., Li, J., & Zhou, Y. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-018-07147-0 · Cited by 68
Self-citationIntratumoral CD8 + T cells with stem cell–like properties: Implications for cancer immunotherapy
Held, W., Siddiqui, I., Schaeuble, K., & Speiser, D. E. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aay6863 · Cited by 56
Elliott, J. A., O’Farrell, N. J., King, S., Halpenny, D. F., Malik, V. K., Muldoon, C. B., Johnston, C., & Reynolds, J. V. (2014) · British journal of surgery · doi:10.1002/bjs.9670 · Cited by 52
Identifying the source of tumour-infiltrating T cells
Vodnala, S. K., & Restifo, N. P. (2019) · Nature · doi:10.1038/d41586-019-03670-6 · Cited by 5
Cited by
Liu, J., Yang, Y., Liu, Z., Fu, X., Cai, X., Li, H., Zhu, L., Shen, Y., Zhang, H., Sun, Y., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004291 · Cited by 282
Self-citationKato, K., Machida, R., Ito, Y., Daiko, H., Ozawa, S., Ogata, T., Hara, H., Kojima, T., Abe, T., Bamba, T., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00745-1 · Cited by 280
Metadata
- Authors
- Li, C., Zhao, S., Zheng, Y., Han, Y., Chen, X., Cheng, Z., Wu, Y., Feng, X., Qi, W., Chen, K., Xiang, J., Li, J., Lerut, T., & Li, H.
- Venue
- European Journal of Cancer
- Publisher
- Elsevier BV
- Published
- 2021-02
- Volume
- 144
- Pages
- 232-241
- ISSN
- 0959-8049 (ISSN-L)
- OpenAlex
- W3115014139
- Cited by
- 324
- References
- 33
- FWCI
- 27.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.